| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences | ||
| Mo | RevMed CEO on tackling "complex" launch for wonder pancreatic drug | ||
| Mo | Flagship Pioneering expands to UK with £100m AI-native lab | ||
| Mo | Sofinnova Partners backs European life sciences sector with €725M raise | ||
| Mo | AstraZeneca secures FDA approval for Imfinzi combo in MIBC | ||
| Mo | FDA rejects Summit's ivonescimab application for lung cancer | ||
| Mo | HLTH 2026: Potential 2028 US presidential contender Mark Kelly warns pharma over profits | ||
| Fr | FDA puts commissioner's priority voucher framework on ice | ||
| Fr | Neurosterix pockets $105m to advance neuropsychiatry pipeline | ||
| Fr | BMS sets unified research and development structure for 2027 | ||
| Fr | Takeda begins US distribution of narcolepsy type 1 drug Orzeyful | ||
| Do | Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval | ||
| Do | Blackstone backs Pfizer's obesity ambitions with $1.5bn fund | ||
| Do | Beyond GLP-1RA's: Novel mechanisms and combos to shape future of obesity market | ||
| Do | FDA and EMA waive paediatric studies for Shanton's gout candidate | ||
| Do | Life-extending peptides are likely not around the corner | ||
| Do | Litmys and PharmaACE partner on pharma commercial forecasting | ||
| Mi | AstraZeneca acquires bacterial vaccine biotech, Omniose | ||
| Mi | Longevity sector ambitions outpace regulatory and investment frameworks | ||
| Mi | Moderna's CEO eyes Keytruda-eclipsing future for personalised cancer vaccine | ||
| Mi | ProBio signs global antibody licensing deal with AbTis | ||
| Mi | Lilly-backed Oyster Therapeutics raises $60m for neurological degraders | ||
| 10.11. | VC funding in Europe falls short at early-stage investment hurdles | ||
| 10.11. | Pentagon drops WuXi AppTec from Chinese military company list | ||
| 10.11. | China's burgeoning novel medicines success presents opportunity for Europe |